Articles, guides, and regulatory updates from our community.
Systematic review of 142 studies reveals newer antidiabetic drugs are generally cost-effective, though access varies by income level and drug pricing.
By Peptide Association Research Team
Systematic review of 142 studies reveals newer diabetes drugs show cost-effectiveness, but affordability varies by country income levels and treatment timing.
By Peptide Association Research Team
Recent research reveals 81% of newer antidiabetic drugs are cost-effective in developed countries, but accessibility remains limited in developing nations.
By Peptide Association Research Team